| Preview | Issue Date | Title / Name | Author(s) | Type |
| 2019 | A Victorian clinician-based survey on current practices for breast cancer staging in pregnancy | Herbison, Harriet; Miller, Abigail; Hart, Christopher D.; Hayes, Theresa; Shnier, Darryl, et al | Conference Paper | |
| 2022 | Achieving equitable access to cancer care and clinical trials in regional Australia: A networked approach to expand capacity and implement COSA teletrials model | Underhill, Craig; Long, Donna; Collins, Ian M.; Brown, Stephen; Harris, Samuel, et al | Conference Paper | |
| 2018 | Cardiotoxicity in advanced HER2 positive breast cancer in real world Australian patients receiving HER2-targeted therapy in the first-line setting | Conduit, C.; King, Rossa; De Boer, Richard; Gibbs, Peter; Lok, Sheau Wen, et al | Conference Paper | |
| 2022 | CDK4/6 Inhibitors (CKD4/6i) in advanced hormone-receptor-positive (HR+) HER2-negative (HER2-) breast cancer: Prescribing practices and outcomes in a real-world, Australian cohort | Javaid, Anadil; Lok, Sheau Wen; Wong, Vanessa; Baron-Hay, Sally; Boyle, Fran, et al | Conference Paper | |
| 2019 | Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years | Mileshkin, Linda R.; Sivakumaran, Tharani; Etemadmoghadam, Dariush; Tothill, Richard; Fellowes, Andrew, et al | Conference Paper | |
 | Jun-2022 | DNA sequencing and gene-expression profiling assists in making a tissue of origin diagnosis in cancer of unknown primary | Posner, A.; Prall, Owen W. J.; Sivakumaran, Tharani; Etemadamoghadam, D.; Thio, N., et al | Journal Article | |
| 2018 | Management of brainmetastases in patients with HER2 positive breast cancer-a real world Australian experience | Moldovan, Cristina A.; King, Rossa; Lok, Sheau Wen; De Boer, Richard; Gibbs, Peter, et al | Conference Paper | |
| 2021 | MO01.39 Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity | Spigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| 2019 | OA03.03 Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer | Paz-Ares Rodriguez, L.; Spigel, David R.; Chen, Yuanbin; Jove, Maria; Juan, O., et al | Conference Paper | |
| 2021 | P48.14 RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting | Paz-Ares, Luis; Spigel, David R.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| 2020 | P7 Are women commencing Neoadjuvant Chemotherapy (NAC) for Primary Breast Cancer (PBC) more likely to experience distress compared to women undergoing surgical intervention or Adjuvant Chemotherapy (AC)? | Hay, R. L.; Pascoe, E.; Hay, Rebecca | Conference Paper | |
| 2019 | Prostate cancer outcome disparity in South West Victoria | Dean, Samantha L.; Matheson, Leigh M.; Davidson, Adee J.; Grills, Richard; Kearns, Paul, et al | Conference Paper | |
| 2020 | Real world outcomes in elderly patients with HER2 positive advanced breast cancer | Evans, Nicole; Anton, Angelyn; Wong, Rachel; Lok, Sheau Wen; De Boer, Richard, et al | Conference Paper | |
| 2021 | Real world outcomes in elderly women with HER2 positive advanced breast cancer | Evans, Nicole; Anton, Angelyn; Wong, Rachel; Lok, Sheau Wen; De Boer, Richard, et al | Conference Paper | |
 | 2020 | Real World Outcomes in Elderly Women with HER2-Positive Advanced Breast Cancer | Evans, Nicole; Anton, Angelyn; Wong, Rachel; Lok, Sheau Wen; De Boer, Richard, et al | Conference Paper | |
| 2021 | Real-world outcomes in patients with brain metastases secondary to HER2-positive breast cancer: An Australian multi-centre registry-based study | Tung, Iris; Moldovan, Cristina; Wong, Vanessa; De Boer, Richard; Gibbs, Peter, et al | Conference Paper | |
| 2020 | Real-world uptake of bone modifying agents in advanced breast cancer with bone metastases-Prospective data from a multi-site Australian registry | Wong, Vanessa; De Boer, Richard; Anton, Angelyn; Malik, Laeeq; Greenberg, Sally, et al | Conference Paper | |
| 2020 | RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC) | Ponce, Santiago; Brendel, K.; Spigel, David R.; Chen, Yuanbin; Jove Casulleras, M., et al | Conference Paper | |
| 2020 | RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity | Spigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| 2020 | RESILIENT part II: An open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy | Spigel, David R.; Paz-Ares, Luis G.; Moore, Yan; Zhang, Bin; Dowlati, Afshin, et al | Conference Paper | |
